|
WASHINGTON, DC USA -- PHARMA UPDATE NEWS SERVICE™ -- APRIL 5, 2019: As the first quarter of 2019, we decided to turn our focus to the dynamic duo of False Claims Act and Anti-kickback Statute. Starting things out, we look back at FY2018 recoveries and settlements to see what the data can tell us about the future. Next, we examine the Dechert LLP annual survey of shareholder actions to see how this increased risk and enforcement actions involving false claim allegations go hand-in-hand.
We also feature a two-part series on the Granston memo and its impacts on qui tam litigation. Then we move on to cover the recent changes to the anti-kickback landscape with passage of the Eliminating Kick-Backs and Recovery Act of 2018. Rounding out the issue, Porzio Life Sciences presents a compelling case on using Big Data and AI can improve most compliance programs.
FEATURE - FALSE CLAIMS ACT
THE RISE AND (MOSTLY) FALL OF FALSE CLAIMS ACT RECOVERIES
By Jennifer O'Leary, JD, LICSW, Staff Writer for Policy and Medicine Compliance Update
Topic tags: FCA, Granston, Yates
SHAREHOLDER LITIGATION
Life Sciences Securities Litigation -- A Significant Risk Lurking In The Background
By Carolyn Greene, Staff Writer, Policy & Medicine Compliance Update
Topic tags: Dechert, Litigation, Securities, Shareholders, Survey
QUI TAM LITIGATION
Gazing Into The Crystal Ball (Part 1) -- Qui Tam Litigation After Granston's Memo
By Gwendolyn Ball, Staff Writer, Policy & Medicine Compliance Update
Topic tags: FCA, Granston Memo, QUI TAM
Gazing Into The Crystal Ball (Part 2) -- The Impact To Escobar After Granston's Memo
By Robert N. Wilkey, Esq., Senior Staff Writer for Life Science Compliance Update
Topic tags: Escobar, FCA, Granston Memo, QUI TAM
ANTI-KICKBACK STATUTE
Remaking The Anti-Kickback Landscape -- EKRA Adds A New Rule To The Existing Healthcare Fraud Enforcement Spectrum
By Jennifer O'Leary, JD, LICSW, Staff Writer for Policy & Medicine Compliance Update
Topic tags: EKRA, Inducements, Kickbacks, Safe Harbors
COMPLIANCE OPERATIONS
Big Data Presents Big Opportunities: Using Artificial Intelligence To Minimize The Risks Associated With HCP Engagements
By Stephanie M. Garfield, JD, Compliance Associate and Michael T. O'Connor, Vice President, Compliance Technology, Porzio Life Sciences
Topic tags: AI, Big data, HCPs, Kickbacks, Machine Learning
Thank you for relying on Policy & Medicine Compliance Update to keep you up-to-date on the pharmaceutical, biotechnology, and device manufacturing industries.
|
